- Trials with a EudraCT protocol (19)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
19 result(s) found for: Sex assignment.
Displaying page 1 of 1.
EudraCT Number: 2007-002101-50 | Sponsor Protocol Number: ACU01-100 | Start Date*: 2007-06-11 | |||||||||||||||||||||
Sponsor Name:Acuity Pharmaceuticals, LLC | |||||||||||||||||||||||
Full Title: A Phase 2, randomized, double-masked, placebo-controlled, parallel-assignment study of topical N-Chlorotaurine (NCT) formulated with ammonium chloride administered for 10 days in patients with epid... | |||||||||||||||||||||||
Medical condition: Epidemic adenoviral keratoconjunctivitis (EKC) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: AT (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002142-13 | Sponsor Protocol Number: P06241/P202 | Start Date*: 2012-05-30 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp | |||||||||||||
Full Title: A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone Furoate/Formoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in ... | |||||||||||||
Medical condition: Persistent Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) EE (Completed) CZ (Completed) LV (Completed) GB (Completed) ES (Completed) DE (Completed) IE (Completed) SK (Completed) PL (Completed) IT (Completed) BG (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005959-42 | Sponsor Protocol Number: CN138-502 | Start Date*: 2008-06-18 | |||||||||||
Sponsor Name:Bristol Myers Squibb International Corporation | |||||||||||||
Full Title: A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Adjunctive Aripiprazole Therapy in the Treatment of Mania in Bipolar I Disorder Pat... | |||||||||||||
Medical condition: Bipolar I Mania (manic or mixed episode) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) ES (Completed) CZ (Completed) AT (Completed) HU (Completed) IT (Completed) PL (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001280-24 | Sponsor Protocol Number: VE202-002 | Start Date*: 2022-07-20 | |||||||||||
Sponsor Name:Vedanta Biosciences, Inc. | |||||||||||||
Full Title: Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of VE202 in Patients with Mild-to-Moderate Ulcerative Colitis | |||||||||||||
Medical condition: Mild-to-moderate ulcerative colitis (UC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) HU (Trial now transitioned) LT (Trial now transitioned) BG (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-018284-42 | Sponsor Protocol Number: LEVVPA | Start Date*: 2012-12-19 | |||||||||||
Sponsor Name:University Medical Centre Groningen | |||||||||||||
Full Title: Double-blind randomized trial comparing efficacy, safety and tolerance between Levetiracetam monotherapy and Valproic acid monotherapy in children with newly diagnosed epilepsy | |||||||||||||
Medical condition: epilepsy | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001217-42 | Sponsor Protocol Number: CN138-489 | Start Date*: 2007-09-20 | |||||||||||
Sponsor Name:Bristol Myers Squibb International Corporation | |||||||||||||
Full Title: A 16-Week, Multicenter, Randomized, Open-label Study to Assess the Effects of Aripiprazole versus other Atypical Antipsychotics in the Treatment of Schizophrenic Patients with Metabolic Syndrome | |||||||||||||
Medical condition: Subjects with schizophrenia who developed metabolic syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) HU (Prematurely Ended) GR (Prematurely Ended) CZ (Completed) ES (Completed) BE (Completed) DK (Prematurely Ended) DE (Prematurely Ended) FI (Prematurely Ended) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005235-14 | Sponsor Protocol Number: P05042 | Start Date*: 2007-07-11 | |||||||||||
Sponsor Name:Integrated Therapeutics Group Inc | |||||||||||||
Full Title: A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users | |||||||||||||
Medical condition: Opioid dependence | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) GB (Completed) ES (Completed) CZ (Completed) PT (Completed) SI (Completed) DE (Completed) IE (Completed) IT (Completed) LT (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-001624-14 | Sponsor Protocol Number: LE3301 | Start Date*: 2022-11-15 | |||||||||||
Sponsor Name:Pharming Technologies B.V. | |||||||||||||
Full Title: An Open-Label, Single Arm Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Leniolisib in Pediatric Patients (Aged 4 to 11 Years) With APDS (Activated Phosphoinositide 3-Kina... | |||||||||||||
Medical condition: Activated Phosphoinositide 3-Kinase Delta Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001432-31 | Sponsor Protocol Number: CA190001 | Start Date*: 2008-04-11 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 1/2a, Ascending Multiple-Dose Study to Evaluate the Safety, Efficacy and Pharmacokinetics of BMS-753493 in Subjects with Advanced Cancer. Revised Protocol 02, incorporating Protocol Amend... | |||||||||||||
Medical condition: Advanced Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001433-34 | Sponsor Protocol Number: CA190002 | Start Date*: 2008-03-14 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 1/2, Ascending Multiple-Dose Study to Evaluate the Safety, Efficacy and Pharmacokinetics of BMS-753493 in Subjects with Advanced Cancer. Revised Protocol 04, incorporating Protocol Amendme... | |||||||||||||
Medical condition: Advanced cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001185-41 | Sponsor Protocol Number: POINT | Start Date*: 2013-11-26 | ||||||||||||||||
Sponsor Name:University of California San Francisco Stroke Sciences Group | ||||||||||||||||||
Full Title: Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial, a randomized, double blind, multicentre clinical trial | ||||||||||||||||||
Medical condition: Transient Ischemic Attack and Minor Stroke | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) ES (Completed) DE (Prematurely Ended) FI (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-000245-33 | Sponsor Protocol Number: VN21 | Start Date*: 2022-05-31 | |||||||||||
Sponsor Name:Medical University of Lublin | |||||||||||||
Full Title: To evaluate the effect of low-dose naltrexone (LDN) on pain perception and quality of life in women | |||||||||||||
Medical condition: Vulvodynia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: PL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002289-33 | Sponsor Protocol Number: 601-0018 | Start Date*: 2023-02-01 | ||||||||||||||||
Sponsor Name:Pulmatrix, Inc. | ||||||||||||||||||
Full Title: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Effect of Dose and Duration of Treatment of Itraconazole Administered as a Dry Powder for Inhalation (PUR1900) on S... | ||||||||||||||||||
Medical condition: Allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-005234-21 | Sponsor Protocol Number: P04843 | Start Date*: 2007-11-28 | |||||||||||
Sponsor Name:Schering-Plough Research Institute | |||||||||||||
Full Title: A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid-Dependent Subjects. | |||||||||||||
Medical condition: Opioid dependance | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) GB (Completed) SE (Completed) PT (Completed) DK (Completed) LT (Completed) SI (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-007504-28 | Sponsor Protocol Number: SCH-P#418131-04223 | Start Date*: 2012-02-06 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A 12-Week, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Mometasone Furoate Metered Dose Inhaler in the Treatment of Children Ages 5 to 11 Years With Persistent Asthma | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) EE (Completed) HU (Completed) PL (Completed) GR (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003567-66 | Sponsor Protocol Number: T817MAEU201 | Start Date*: 2019-06-11 | ||||||||||||||||
Sponsor Name:FUJIFILM Toyama Chemical Co., Ltd. | ||||||||||||||||||
Full Title: A Phase 2 multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of T 817MA in patients with mild cognitive impairment due to Alzheimer... | ||||||||||||||||||
Medical condition: Mild cognitive impairment due to Alzheimer's Disease or mild Alzheimer's Disease. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) ES (Ongoing) HU (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002942-12 | Sponsor Protocol Number: P04737 | Start Date*: 2007-10-22 | |||||||||||
Sponsor Name:Schering-Plough Research Institute | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With a History of Atherosclerotic Dis... | |||||||||||||
Medical condition: Documented coronary artery disease, postischemic cerebrovascular disease or peripheral artery disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DK (Completed) NL (Completed) SE (Completed) PT (Completed) FI (Completed) CZ (Completed) GB (Completed) BE (Completed) IT (Completed) ES (Completed) AT (Completed) DE (Completed) PL (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002809-31 | Sponsor Protocol Number: P04736 | Start Date*: 2008-04-30 | |||||||||||
Sponsor Name:Schering Plough Research Institute, a Division of Schering Corporation | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With Acute Coronary Syndrome: Thrombi... | |||||||||||||
Medical condition: Acute Coronary Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) FR (Completed) DK (Prematurely Ended) FI (Prematurely Ended) GB (Prematurely Ended) SE (Prematurely Ended) PT (Prematurely Ended) DE (Prematurely Ended) NL (Completed) AT (Completed) ES (Prematurely Ended) IT (Prematurely Ended) HU (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002248-98 | Sponsor Protocol Number: TN-10 | Start Date*: 2016-01-15 | |||||||||||
Sponsor Name:TrialNet Coordinating Center | |||||||||||||
Full Title: Anti-CD3 mAb (teplizumab) for prevention of diabetes in relatives at-risk for Type 1 diabetes mellitus | |||||||||||||
Medical condition: Anti-CD3 monoclonal antibody is to be used for the prevention of type 1 diabetes mellitus in relatives at risk for developing the disease. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
